Bayer exec: Trump pharma tariffs would negatively impact R&D

If President Trump’s threat to impose tariffs on pharmaceutical products goes through, it would have severe consequences for industry R&D efforts, according to a Bayer (OTCPK:BAYZF) pharma executive.

“Every dollar we spend on tariffs is a dollar we can’t spend